Tags

Type your tag names separated by a space and hit enter

Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.
Clin Chem Lab Med 2004; 42(10):1092-7CC

Abstract

Anti-tissue transglutaminase, previously held to be identical to anti-endomysial antibodies in celiac sprue, has been reported in inflammatory bowel disease patients. To investigate these data further, we evaluated serum and intestinal anti-tissue transglutaminase in inflammatory bowel disease patients, with respect to the Crohn's disease activity index and the integrated disease activity index. Study population comprised: 49 patients with Crohn's disease and 29 patients with ulcerative colitis; 45 patients with celiac sprue and 85 autoimmune patients as disease controls; and 58 volunteers as healthy controls. Immunoglobulin A (IgA) anti-recombinant human tissue transglutaminase and anti-endomysial antibody detection in sera and fecal supernatants were performed. Adsorption of positive sera with recombinant human tissue transglutaminase were also performed. Marked increased anti-tissue transglutaminase concentrations were found in celiac sprue, while low-positive values were also found in Crohn's disease and ulcerative colitis. Anti-endomysial antibodies were detectable only in celiac sprue. Antigen adsorption resulted in a significant reduction of the anti-tissue transglutaminase either in celiac sprue or inflammatory bowel disease sera. A significant correlation between anti-tissue transglutaminase and Crohn's disease activity index or integrated disease activity index scores was found. Anti-tissue transglutaminase was also detectable in fecal supernatants from inflammatory bowel disease patients. Data highlight that both circulating and intestinal anti-tissue transglutaminases are detectable in inflammatory bowel disease, and that they are related to disease activity. These features underline that, in addition to anti-tissue transglutaminase, an anti-endomysial antibody test is necessary in the diagnostic work-up of celiac sprue, especially in patients with known inflammatory bowel disease.

Authors+Show Affiliations

Department of Clinical Sciences, University La Sapienza, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15552265

Citation

Di Tola, Marco, et al. "Anti-tissue Transglutaminase Antibodies in Inflammatory Bowel Disease: New Evidence." Clinical Chemistry and Laboratory Medicine, vol. 42, no. 10, 2004, pp. 1092-7.
Di Tola M, Sabbatella L, Anania MC, et al. Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. Clin Chem Lab Med. 2004;42(10):1092-7.
Di Tola, M., Sabbatella, L., Anania, M. C., Viscido, A., Caprilli, R., Pica, R., ... Picarelli, A. (2004). Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. Clinical Chemistry and Laboratory Medicine, 42(10), pp. 1092-7.
Di Tola M, et al. Anti-tissue Transglutaminase Antibodies in Inflammatory Bowel Disease: New Evidence. Clin Chem Lab Med. 2004;42(10):1092-7. PubMed PMID: 15552265.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. AU - Di Tola,Marco, AU - Sabbatella,Luigi, AU - Anania,Maria Cristina, AU - Viscido,Angelo, AU - Caprilli,Renzo, AU - Pica,Roberta, AU - Paoluzi,Paolo, AU - Picarelli,Antonio, PY - 2004/11/24/pubmed PY - 2005/4/6/medline PY - 2004/11/24/entrez SP - 1092 EP - 7 JF - Clinical chemistry and laboratory medicine JO - Clin. Chem. Lab. Med. VL - 42 IS - 10 N2 - Anti-tissue transglutaminase, previously held to be identical to anti-endomysial antibodies in celiac sprue, has been reported in inflammatory bowel disease patients. To investigate these data further, we evaluated serum and intestinal anti-tissue transglutaminase in inflammatory bowel disease patients, with respect to the Crohn's disease activity index and the integrated disease activity index. Study population comprised: 49 patients with Crohn's disease and 29 patients with ulcerative colitis; 45 patients with celiac sprue and 85 autoimmune patients as disease controls; and 58 volunteers as healthy controls. Immunoglobulin A (IgA) anti-recombinant human tissue transglutaminase and anti-endomysial antibody detection in sera and fecal supernatants were performed. Adsorption of positive sera with recombinant human tissue transglutaminase were also performed. Marked increased anti-tissue transglutaminase concentrations were found in celiac sprue, while low-positive values were also found in Crohn's disease and ulcerative colitis. Anti-endomysial antibodies were detectable only in celiac sprue. Antigen adsorption resulted in a significant reduction of the anti-tissue transglutaminase either in celiac sprue or inflammatory bowel disease sera. A significant correlation between anti-tissue transglutaminase and Crohn's disease activity index or integrated disease activity index scores was found. Anti-tissue transglutaminase was also detectable in fecal supernatants from inflammatory bowel disease patients. Data highlight that both circulating and intestinal anti-tissue transglutaminases are detectable in inflammatory bowel disease, and that they are related to disease activity. These features underline that, in addition to anti-tissue transglutaminase, an anti-endomysial antibody test is necessary in the diagnostic work-up of celiac sprue, especially in patients with known inflammatory bowel disease. SN - 1434-6621 UR - https://www.unboundmedicine.com/medline/citation/15552265/Anti_tissue_transglutaminase_antibodies_in_inflammatory_bowel_disease:_new_evidence_ L2 - https://www.degruyter.com/doi/10.1515/CCLM.2004.225 DB - PRIME DP - Unbound Medicine ER -